Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The role of the molecular footprint of EGFR in tailoring treatment decisions in NSCLC.

Journal of clinical pathology - 1 Jan 2012

Gately Kathy, O'Flaherty John, Cappuzzo Frederico, Pirker Robert, Kerr Keith, O'Byrne Kenneth

Abstract excerpt

The majority of patients with non-small-cell lung cancer (NSCLC) present with advanced disease, with targeted therapies providing some improvement in clinical outcomes. The epidermal growth factor receptor (EGFR) tyrosine kinase (TK) plays an important role in the pathogenesis of NSCLC. Tyrosine kinase inhibitors (TKIs), which target the EGFR TK domain, have proven to be an effective treatment strategy; however,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Molecular Targeted Therapy

Share to Neoplasm Recurrence, Local

Share to Patient Selection

Share to Precision Medicine

Share to Protein Kinase Inhibitors

Source

Identifiers

PMID: 22039281
DOI: 10.1136/jclinpath-2011-200275

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The role of the molecular footprint of EGFR in tailoring treatment decisions in NSCLC.PMID 22039281Read ↗

Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer.Semantic proximity Read ↗

Pharmacogenetics of EGFR in Lung Cancer: Perspectives and Clinical ApplicationsSemantic proximity Read ↗

EGFR-targeted therapy for non-small cell lung cancer: focus on EGFR oncogenic mutation.Semantic proximity Read ↗

Molecular targeted therapy of lung cancer: EGFR mutations and response to EGFR inhibitors.Semantic proximity Read ↗

Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC.Semantic proximity Read ↗

Genetic profiling and epidermal growth factor receptor-directed therapy in nonsmall cell lung cancer.Semantic proximity Read ↗

Pharmacogenomics of EGFR-targeted therapies in non-small cell lung cancer: EGFR and beyond.Semantic proximity Read ↗

EGFR Mutations and Lung CancerSemantic proximity Read ↗

The importance of molecular profiling in predicting response to epidermal growth factor receptor family inhibitors in non-small-cell lung cancer: focus on clinical trial results.Semantic proximity Read ↗

Targeting epidermal growth factor receptor in the treatment of non-small-cell lung cancer.Semantic proximity Read ↗

Epidermal growth factor receptor mutations in non-small cell lung cancer: a basic science discovery with immediate clinical impact.Semantic proximity Read ↗

Epidermal growth factor receptor (EGFR) mutations in a series of non-small-cell lung cancer (NSCLC) patients and response rate to EGFR-specific tyrosine kinase inhibitors (TKIs).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.